386 related articles for article (PubMed ID: 30119173)
1. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.
Deng H; Qianqian G; Ting J; Aimin Y
Biomed Pharmacother; 2018 Oct; 106():1072-1081. PubMed ID: 30119173
[TBL] [Abstract][Full Text] [Related]
2. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
3. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
4. MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC.
Wang X; Chen X; Meng Q; Jing H; Lu H; Yang Y; Cai L; Zhao Y
Sci Rep; 2015 Dec; 5():17618. PubMed ID: 26620926
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
Hua L; Zhu G; Wei J
Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
[TBL] [Abstract][Full Text] [Related]
6. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
7. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
Huang Q; Xing S; Peng A; Yu Z
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
[TBL] [Abstract][Full Text] [Related]
8. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
Liu B; Wang R; Liu H
Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
[TBL] [Abstract][Full Text] [Related]
9. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
[TBL] [Abstract][Full Text] [Related]
10. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
[TBL] [Abstract][Full Text] [Related]
12. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
13. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
[TBL] [Abstract][Full Text] [Related]
14. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
16. Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway.
Wang N; Feng T; Liu X; Liu Q
Acta Pharm; 2020 Sep; 70(3):399-409. PubMed ID: 32074070
[TBL] [Abstract][Full Text] [Related]
17. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
18. The malignant property of circHIPK2 for angiogenesis and chemoresistance in non-small cell lung cancer.
Ren M; Song X; Niu J; Tang G; Sun Z; Li Y; Kong F
Exp Cell Res; 2022 Oct; 419(2):113276. PubMed ID: 35863454
[TBL] [Abstract][Full Text] [Related]
19. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1.
Cheng R; Lu C; Zhang G; Zhang G; Zhao G
Oncol Rep; 2017 Apr; 37(4):2129-2136. PubMed ID: 28350100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
